| Bid price | 5.25 | Open price | 5.50 |
|---|---|---|---|
| Ask price | 5.75 | Prev close | 5.50 |
| High price | 5.53 | Spread | 8.70% |
| Low price | 5.25 | Volume | 101,743 |
Register now for FREE live Cyprotex share prices, Cyprotex stock quotes, charts, trades and FREE Cyprotex company fundamentals, market news and much much more. Why not upgrade to a premium service and get Cyprotex Level 2 Data, indepth research tools and investor commentary for Cyprotex (CRX) and other London Stock Exchange equities.
Register now for FREE Cyprotex share price charts
| Name | Cyprotex | Epic | CRX |
|---|---|---|---|
| Activites | Provides in vitro and in silico ADME/PK information to the pharmaceutical industry | Reuters | CRX.L |
| ISIN | GB0031214470 | Google Finance | LON:CRX |
| Share Price (p) | 5.50 | Prev. Share Price (p) | 5.50 |
|---|---|---|---|
| Shares in Issue (m) | 224 | Market Cap (£m) | 12 |
| PE Ratio (x) | Div per share (p) | 0.00 | |
| Div yield (%) | 0.00 | Div cover (x) | |
| EPS (p) | 0.40 | PEG |
Register now for FREE Cyprotex company fundamentals
| Dec.Date | Type | Director | Pos | No. of Shares |
|---|---|---|---|---|
| 18/08/2010 | BUY | Ralph Harris | CH | 707,142 |
| 18/08/2010 | BUY | Anthony Baxter | CEO | 226,285 |
| 18/08/2010 | BUY | John Dootson | FD | 589,285 |
| 25/11/2009 | BUY | Anthony Baxter | CEO | 120,000 |
| 18/09/2009 | BUY | Anthony Baxter | CEO | 121,400 |
Cyprotex has introduced two new services in pre-clinical ADME Tox: PXR and AhR nuclear receptor activation assay and Lysosomal trapping (lysosomotropism) service. The company says PXR and AhR nuclear receptor activation is key in the regulation of certain drug metabolism pathways. Increase in...
/* */ RNS Number : 6227C Cyprotex PLC 03 May 2012 3rd May 2012 Cyprotex PLC Cyprotex Strengthens Product Offering Cyprotex PLC (AIM:CRX), the drug discovery ADME Tox services and information company, today announces...
Register now for FREE Cyprotex company news
I have held CRX for too long, but initially bought on seeing the theoretical advantages of the "systems" for evaluation of drugs at potentially less costs than other systems. I bought the shares initially long out and bought a number of times at lower and lower prices. From the fundamentals...
Is it realistic that given the high expectations for cyprotex that it could reach £3 per share. Partnerships with the big pharma co's could make these shoot north?
hi Does anyone have any suggestions on how high cyprotex could eventually reach if the rumours of partnerships with the big drug companies ever materialise? Is £3 per share realisic? Cheers Michael
Register now for FREE Cyprotex share price discussions